Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Open accessPublished version of a preprint
The DOI matches its Crossref record; 79 of the 94 references it cites were found in a registry or an index; 28 of the 138 sources its claims cite were checked for support.
Abstract
KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment paradigm for patients with KRASG12C-mutated non–small cell lung cancer and colorectal cancer. The success of addressing a previously elusive KRAS allele has fueled drug discovery efforts for all KRAS mutants. Pan-KRAS drugs have the potential to address broad patient populations, including KRASG12D-, KRASG12V-, KRASG13D-, KRASG12R-, and KRASG12A-mutant or KRAS wild-type–amplified cancers, as well as cancers with acquired resistance to KRASG12C inhibitors. Here, we review actively pursued allele-specific and pan-KRAS inhibition strategies and their potential utility. Significance: Mutant-selective KRASG12C inhibitors target a fraction (approximately 13.6%) of all KRAS-driven cancers. A broad arsenal of KRAS drugs is needed to comprehensively conquer KRAS-driven cancers. Conceptually, we foresee two future classes of KRAS medicines: mutant-selective KRAS drugs targeting individual variant alleles and pan-KRAS therapeutics targeting a broad range of KRAS alterations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 4 Not valid · 66 Not checked · 37 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“While KRASG12C inhibitors deliver clinical benefit, all patients who achieved an objective response ultimately progressed on treatment with sotorasib in a Phase II study (24).”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > FURTHER OPPORTUNITIES FOR PAN-KRAS DRUGS > ACQUIRED RESISTANCE TO MUTANT-SELECTIVE KRASG12C INHIBITORS
What the sources say
- Disputedcites [24] Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021; 384: 2371– 81. 34096690 PMC9116274 sourceExperimental — accuracy not yet measured
The Results (Efficacy) report 46 objective responses, but state that at the data cutoff, 16 of those patients were still receiving sotorasib without disease progression. The study therefore does not report that all responders progressed on treatment; it cannot establish what happened to those 16 patients later. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“KRAS is the most frequently mutated oncogene”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > Abstract
What the sources say
- Partly supportedcites [3] Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res 2020; 80: 2969– 74. 32209560 PMC7367715 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) reports that KRAS accounts for 75% of Ras-mutant cancers and is the most frequently mutated of the three Ras isoforms in 19 of 29 cancer types. This supports describing KRAS as frequently mutated, but the paper does not establish the citing sentence’s stronger claim that it is the most frequently mutated oncogene overall. (LLM, conf=0.86)
- Could not verifycites [4] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401– 4. 22588877 PMC3956037 sourceExperimental — accuracy not yet measured
The passages on mutation visualization and alteration frequency (section labeled Abstract; page unavailable) discuss BRCA1, RB-pathway genes, and other examples, but do not address KRAS. Searches for “KRAS most frequently mutated oncogene” and “KRAS” found no passage establishing its mutation-frequency ranking. (LLM, conf=0.75)
- Partly supportedcites [5] AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017; 7: 818– 31. 28572459 PMC5611790 sourceExperimental — accuracy not yet measured
The Comparison with TCGA section reports KRAS mutations in 27% of non–small cell lung cancers and 47% of colorectal cancers in GENIE, supporting that KRAS is frequently mutated in those cancers. It does not establish that KRAS is the most frequently mutated oncogene across human cancers, as the citing sentence states. No page number is available in our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In heterozygous KRAS mutant tumor cells, RAS signaling can be supplemented and cross-regulated by RTK-WT RAS signaling.”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > INDIRECT THERAPEUTIC PAN-KRAS CONCEPTS
What the sources say
- Partly supportedcites [12] Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov 2021; 11: 142– 57. 32816843 PMC7892644 sourceExperimental — accuracy not yet measured
The Introduction describes SOS1-mediated activation of RAS and feedback regulation, and the Results report signaling measurements in heterozygous KRAS-mutant tumor cells. The paper does not explicitly show that RTK-driven wild-type RAS signaling supplements and cross-regulates signaling in those heterozygous cells; that specific connection is not established by the cited passages. Page numbers are unavailable in our copy. (LLM, conf=0.82)
- Partly supportedcites [43] Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clin Cancer Res 2021; 27: 342– 54. 33046519 sourceExperimental — accuracy not yet measured
The section on TNO155 and KRAS G12C inhibitors describes feedback signaling through wild-type KRAS, HRAS, and NRAS and reports combination effects in heterozygous KRAS G12C cell lines (page not available in our copy). This supports the proposed interaction between mutant-KRAS and wild-type-RAS signaling, but the paper’s evidence is specific to KRAS G12C models and inhibitor-induced feedback, not heterozygous KRAS-mutant tumor cells generally. (LLM, conf=0.85)
- Not checked yetcites [45] Hofmann MH, Lu H, Duenzinger U, Gerlach D, Trapani F, Machado AA, Trial in process: phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. Cancer Res 2021; 81(Suppl13):abstrCT210. source
- Partly supportedcites [46] Hayes TK, Der CJ. Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov 2013; 3: 24– 6. 23319767 PMC3808242 sourceExperimental — accuracy not yet measured
The Findings section describes RTK signaling activating WT Ras and potentially bypassing blocked mutant-Ras signaling; it also describes antagonism between mutant Ras and EGFR signaling. But the studied KRAS-mutant cell line was homozygous, not heterozygous, for mutant KRAS, so the source does not establish the claim for heterozygous KRAS-mutant tumor cells. No page number is provided in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Initial data suggest that a higher tumor mutational burden occurs in the overall KRAS mutant population, potentially resulting in improved response to immune checkpoint inhibition (71).”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > PATIENT POPULATIONS ADDRESSABLE BY PAN-KRAS DRUGS
What the sources say
- Partly supportedcites [71] Sun L, Hsu M, Cohen RB, Langer CJ, Mamtani R, Aggarwal C. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol 2021; 7: 937– 9. 33856403 PMC8050787 sourceExperimental — accuracy not yet measured
The introduction (page not provided) associates KRAS variants in NSCLC with responsiveness to ICI monotherapy, and the Results report better survival with ICI monotherapy for patients with KRAS variants than for those with KRAS wild type. But the paper does not report tumor mutational burden or link it to the observed outcomes; its analysis is also restricted to advanced, PD-L1-high nonsquamous NSCLC, not the overall KRAS-mutant population. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Non-G12C KRAS mutant NSCLC tumors are distinct from KRASG12C-mutated lung cancers in terms of co-mutation of tumor suppressor genes.”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > PATIENT POPULATIONS ADDRESSABLE BY PAN-KRAS DRUGS
What the sources say
- Could not verifycites [5] AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017; 7: 818– 31. 28572459 PMC5611790 sourceExperimental — accuracy not yet measured
The Comparison with TCGA section reports KRAS p.G12 enrichment and KRAS–EGFR mutual exclusivity in non–small cell lung cancer. It does not compare G12C with non-G12C tumors or report differences in tumor-suppressor co-mutations; searches for those terms and for TP53, STK11, and KEAP1 found no matching passage in our copy. (LLM, conf=0.76)
- Not checked yetcites [67] Aggarwal S WS, Hsu H, Tu H, Carrigan G, Wang X, Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB). Ann Oncol 2020; 31(Suppl4): S754– S840. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
53 more claims · 2 with their cited sources checked
Create a free account to see all 121 claims and to verify the 110 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 53
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Third, 12–14% of KRAS mutations in NSCLC are KRASG12C, presenting a promising patient group that would directly benefit from KRAS(G12C) inhibition89.”
From Advances in covalent drug discovery (2022) · cites this paper as [89]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Collectively, these findings indicate that resistance to KRAS-targeted therapy is driven by a complex interplay between KRAS-specific genomic evolution, general signaling adaptation, phenotypic plasticity, and tumor microenvironmental dynamics [12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutations are most commonly found in non-small cell lung cancer (NSCLC; 30~35%), pancreatic ductal adenocarcinoma (PDAC; ~90%) and colorectal cancer (CRC; 45~50%) [10–12], and are associated with a worse prognosis [13–15].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Preclinical and clinical studies, however, have demonstrated that cancers lose sensitivity to KRASG12Ci and re-establish RAS-MAPK signaling through multiple mechanisms, including increased activation of mutant or wild-type (WT) RAS and/or gain of upstream/downstream bypass events1,7,9,10,13,14.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Unlike KRAS G12C, KRAS G12D lacks a targetable cysteine residue for covalent inhibition [12,14,15].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [12]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“In addition to small molecule inhibitors, several strategies of KRAS inhibition have been investigated in PDAC, most notably using small interfering RNAs and inhibitory exosomes (82, 83), both in ongoing clinical trials.”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“Shokat and colleagues (14) of compounds tethered to the cysteine of KRASG12C.”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Preclinical studies suggest that sotorasib and adagrasib can induce a more proinflammatory and TIL-infiltrated TME in mouse models, translating into durable complete responses in combination with anti–PD-1 therapy (21, 74).”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D, and Q61H) was detected as one mechanism of acquired resistance in patients with metastatic colorectal cancer who relapsed on cetuximab or panitumumab treatment (78, 79).”
BackgroundSelf-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · cited 3×
“Sotorasib has recently received FDA approval for the treatment of patients with advanced KRASG12C-mutant NSCLC following at least one prior systemic therapy, based on data from the phase I/II CodeBreaK 100 study (24).”
BackgroundMethodKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · cited 1×
“Importantly, KRAS, ERBB2, and FGFR2 amplifications are mutually exclusive in stomach cancer (91), with the latter two types of amplification subtypes already representing actionable alterations for precision medicine approaches (92, 93).”
BackgroundAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 1×
“In its oncogenic form, KRAS remains predominantly in the active ON state as GTP hydrolysis, by its intrinsic GTPase function and enzymes, such as GAPs, is impaired (7, 8).”
BackgroundSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 1×
“SHP2 inhibitors stabilize the auto-inhibited conformation of the enzyme and thereby disrupt SOS1-mediated nucleotide exchange of KRAS (11, 35, 36).”
BackgroundDiscovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · cited 2×
“In addition, KRASG12C active state inhibitors are expected to address adaptive changes of KRAS resulting in the production of new, active KRAS (10).”
BackgroundTanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · cited 2×
“Two recent reports provide much-awaited first insights into the mechanisms underlying acquired resistance to the KRASG12C inhibitors in the clinic (64, 65).”
BackgroundMethodNeurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · cited 2×
“In colorectal cancer, RTK dependency and signaling rebound kinetics have been identified as potential mechanisms underlying resistance to KRASG12C inhibition (23, 26, 27).”
BackgroundSelf-citationVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
The American Cancer Society’s Facts & Figures: 2020 Edition
Hallquist Viale, R. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.2.1 · Cited by 484
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Self-citationNichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · cited 1×
“SHP2 inhibitors stabilize the auto-inhibited conformation of the enzyme and thereby disrupt SOS1-mediated nucleotide exchange of KRAS (11, 35, 36).”
BackgroundGenetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · cited 1×
“Barbacid’s studies in mice indicate that in contrast to the late- and slow-onset effects obtained with genetic KRAS inactivation, the ablation of all RAS isoform expression causes death of adult mice within a few weeks of induction (60, 61).”
BackgroundGolan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336 · cited 1×
“In addition to small molecule inhibitors, several strategies of KRAS inhibition have been investigated in PDAC, most notably using small interfering RNAs and inhibitory exosomes (82, 83), both in ongoing clinical trials.”
BackgroundGarcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298 · cited 1×
“SHP2 inhibitors stabilize the auto-inhibited conformation of the enzyme and thereby disrupt SOS1-mediated nucleotide exchange of KRAS (11, 35, 36).”
BackgroundPROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S.-M., Dong, J., Xu, Z.-Y., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 292
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265 · cited 2×
“4) and fall into six different classes: i) KRAS mutations in the switch II pocket that block inhibitor binding (secondary mutations in KRAS residues R68, H95, or Y96), ii) activating KRAS mutations (G12D, G12R, G12V, G13D, or Q61H) likely in a trans allele configuration, iii) cis allele conversion of the KRASG12C codo…”
BackgroundSelf-citationMisale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
Self-citationAdachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249 · cited 1×
“4) and fall into six different classes: i) KRAS mutations in the switch II pocket that block inhibitor binding (secondary mutations in KRAS residues R68, H95, or Y96), ii) activating KRAS mutations (G12D, G12R, G12V, G13D, or Q61H) likely in a trans allele configuration, iii) cis allele conversion of the KRASG12C codo…”
BackgroundTargeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239 · cited 1×
“In its oncogenic form, KRAS remains predominantly in the active ON state as GTP hydrolysis, by its intrinsic GTPase function and enzymes, such as GAPs, is impaired (7, 8).”
BackgroundAtypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Tissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Bispecific antibodies targeting mutant RAS neoantigens
Douglass, J., Hsiue, E. H.-C., Mog, B. J., Hwang, M. S., DiNapoli, S. R., Pearlman, A. H., Miller, M. S., Wright, K. M., Azurmendi, P. A., Wang, Q., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5515 · Cited by 171
Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0462 · Cited by 168
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167 · cited 2×
“A combination of a mutant-specific KRAS inhibitor with either a SHP2 inhibitor or a SOS1 inhibitor could effectively block mutant KRAS and wild-type RAS signaling (12, 43, 45, 46).”
BackgroundJänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31076-5 · Cited by 140
Kerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124 · cited 1×
“In addition, SHP2 inhibition may also yield immunomodulatory effects in T cells and macrophages to elicit antitumor immune responses (37).”
BackgroundGTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00514 · Cited by 124 · cited 1×
“Indeed, recently cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
BackgroundBeyond cysteine: recent developments in the area of targeted covalent inhibition
Mukherjee, H., & Grimster, N. P. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.011 · Cited by 95 · cited 1×
“The druggability advantage of covalently targeting the nucleophilic cysteine residue has thus far not materialized for other amino acids (31) and hence it is questionable whether this strategy can be successfully applied to KRAS-mutant oncoproteins beyond KRASG12C.”
BackgroundLu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90 · cited 1×
“SHP2 inhibitors and BI 1701963 are being combined with MEK inhibitors [NCT04294160, NCT03989115 (41), NCT04720976, NCT04111458, and NCT048357] to enhance MAPK pathway modulation and to suppress pathway reactivation elicited by the alleviation of negative feedback control (12, 42).”
BackgroundSun, L., Hsu, M., Cohen, R. B., Langer, C. J., Mamtani, R., & Aggarwal, C. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0546 · Cited by 87
Brana, I., Shapiro, G., Johnson, M. L., Yu, H. A., Robbrecht, D., Tan, D. S.-W., Siu, L. L., Minami, H., Steeghs, N., Hengelage, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3005 · Cited by 79
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30464-2 · Cited by 78 · cited 1×
“Guo and colleagues (56) reported a phase Ib study of the MEK inhibitor VS-6766 (previously known as CH5126766 or RO5126766), which showed promising antitumor activity across a spectrum of KRAS-mutant tumors, including KRASG12V mutation-positive NSCLC.”
BackgroundJohnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31077-7 · Cited by 77
Wainberg, Z. A., Enzinger, P. C., Kang, Y.-K., Yamaguchi, K., Qin, S., Lee, K.-W., Oh, S. C., Li, J., Turk, H. M., Teixeira, A. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.160 · Cited by 76
Ou, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., McCoach, C., Wang, J. S., Gordon, M., Haura, E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.041 · Cited by 73
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-80999-x · Cited by 73 · cited 1×
“Besides its role in cancer cell intrinsic mitogenic signaling, SHP2 mediates signaling through the immune checkpoint receptor PD-1 in T cells (49).”
BackgroundWeiss, J., Yaeger, R. D., Johnson, M. L., Spira, A., Klempner, S. J., Barve, M. A., Christensen, J. G., Chi, A., Der-Torossian, H., Velastegui, K., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2093 · Cited by 73
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
Gao, G., Liao, W., Ma, Q., Zhang, B., Chen, Y., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.004 · Cited by 71 · cited 1×
“Early data suggest that the presence of KRAS alleles other than G12C mutations (75), especially in conjunction with a TP53 comutation, may represent a negative predictive biomarkers for anti–PD-1/PD-L1 immune checkpoint inhibitors in patients with NSCLC (76).”
BackgroundTargeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
Valencia-Sama, I., Ladumor, Y., Kee, L., Adderley, T., Christopher, G., Robinson, C. M., Kano, Y., Ohh, M., & Irwin, M. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3822 · Cited by 62
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 62
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61 · cited 1×
“Early data suggest that the presence of KRAS alleles other than G12C mutations (75), especially in conjunction with a TP53 comutation, may represent a negative predictive biomarkers for anti–PD-1/PD-L1 immune checkpoint inhibitors in patients with NSCLC (76).”
BackgroundZhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60
Schram, A. M., O'Reilly, E. M., O'Kane, G. M., Goto, K., Kim, D., Neuzillet, C., Martín-Romano, P., Duruisseaux, M., Nagasaka, M., Rodon, J. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3003 · Cited by 54
Current status of MEK inhibitors in the treatment of plexiform neurofibromas
Gross, A. M., Dombi, E., & Widemann, B. C. (2020) · Child's Nervous System · doi:10.1007/s00381-020-04731-2 · Cited by 47
Bhonde, M. R., Hanski, M.-L., Notter, M., Gillissen, B. F., Daniel, P. T., Zeitz, M., & Hanski, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209017 · Cited by 47 · cited 1×
“In preclinical experiments, a combination of the topoisomerase I inhibitor irinotecan with a SOS1 inhibitor enhances formation of DNA double-strand breaks in a KRASmutated tumor model (45, 48).”
BackgroundRas signaling is essential for skin development
Drosten, M., Lechuga, C. G., & Barbacid, M. (2014) · Oncogene · doi:10.1038/onc.2013.254 · Cited by 46
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 46
Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0180 · Cited by 43 · cited 1×
“It is apparent that mutations at other sites in KRAS, including codon 12, 13, 59, 61, 117, and 146 mutations, plus some atypical variants not currently included in standard guidelines in KRAS testing, also enhance its oncogenic potential (17).”
BackgroundThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42 · cited 1×
“Pan-KRAS inhibitors and degraders could also become the prime choice for cancers driven by wild-type KRAS, such as KRAS wild-type–amplified or cancers driven by loss of the NF1 tumor suppressor, as well as neurofibromatosis type 1 or its associated malignancies (34, 62, 63).”
BackgroundKoltun, E., Cregg, J., Rice, M. A., Whalen, D. M., Freilich, R., Jiang, J., Hansen, R., Bermingham, A., Knox, J. E., Dinglasan, J., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1260 · Cited by 33
PROTAC-mediated degradation of KRAS protein for anticancer therapeutics
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00584 · Cited by 30
Climbing RAS, the Everest of Oncogenes
Russo, M., Nicolantonio, F. D., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0906 · Cited by 27
Fakih, M., Falchook, G. S., Hong, D. S., Yaeger, R. D., Chan, E., Mather, O., Cardona, P., Dai, T., & Strickler, J. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.955 · Cited by 25
Bendell, J. C., Ulahannan, S. V., Koczywas, M., Brahmer, J. R., Capasso, A., Eckhardt, S. G., Gordon, M. S., McCoach, C. E., Nagasaka, M., Ng, K., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31089-3 · Cited by 25
Suppressing nucleotide exchange to inhibit KRAS-mutant tumors
Zhao, Y., Xue, J. Y., & Lito, P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1331 · Cited by 21
Hofmann, M. H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A. A., Daniele, J. R., Waizenegger, I., Gmachl, M., Rudolph, D., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-ct210 · Cited by 20
Self-citationGiopanou, I., & Pintzas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102859 · Cited by 17 · cited 1×
“Besides its negative predictive role for response to anti-EGFR therapy, KRAS mutation status also has a negative prognostic impact in colorectal cancer and is associated with right-sidedness of tumor location (77).”
BackgroundKRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Nichols, R. J., Cregg, J., Schulze, C. J., Wang, Z., Yang, K., Jiang, J., Whalen, D. M., Hansen, R., Garrenton, L. S., Bermingham, A., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1261 · Cited by 14
Mutant and wild-type Ras: co-conspirators in cancer
Hayes, T. K., & Der, C. J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0521 · Cited by 13
Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-ct019 · Cited by 10
Aggarwal, S., Whipple, S., Hsu, H., Tu, H., Carrigan, G., Wang, X., Ngarmchamnanrith, G., & Chia, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1653 · Cited by 8
Bazhenova, L. A., Liu, S. V., Lin, J. J., Lü, S., Drilon, A. E. D. C., Chawla, S. P., Fakih, M., Krzakowski, M. J., Paz-Ares, L., Blakely, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1055 · Cited by 7
Abstract 99: Evolution of OncoKB, a precision oncology knowledgebase
Suehnholz, S. P., Kundra, R., Zhang, H., Smith, S., Nissan, M., Yao, Y., LaFave, L., Gala, K., Miles, L., Arcila, M. E., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-99 · Cited by 3
Research works printed but not linked: 2
- Kraut N. Expanding the reach of precision oncology by drugging all KRAS mutants. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 May 17–21. Philadelphia (PA): AACR; 2021. PMC9394389 35046095
- Scala AD. Generation and characterization of triple knockout mice for H, N and K-ras genes [dissertation]. Department of Molecular Biology, Faculty of Sciences Autonomous University of Madrid; 2008.
Cited by
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
Self-citationNeoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Metadata
- Authors
- Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Kraut, Norbert
- Venue
- Cancer Discovery
- Published
- 2022-01-19
- Volume
- 12
- Issue
- 4
- Pages
- 924-937
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394389
- OpenAlex
- W4205933836
- Semantic Scholar
- 62e5c29c0dfc65c8d643cf80f4f3e78cdda96ed5
- Cited by
- 336
- References
- 94
- Citations by year
- 2026: 59 · 2025: 86 · 2024: 80 · 2023: 78 · 2022: 33
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS mutation, pan-KRAS inhibitors, KRAS G12D, precision oncology, KRAS-driven cancers, non-small cell lung cancer, colorectal cancer
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Oncogenes, Proto-Oncogene Proteins p21(ras), Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.